Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claudio Rapezzi

Showing results (351-360 of 404) with videos related to

Pageof 41
Sort By:
Journal of Cardiovascular Medicine (Hagerstown, Md.)|October 15, 2008
Anticoagulant drugs in noncompaction: a mandatory therapy?Giovanni Fazio, Giovanni Corrado, Elisabetta Zachara, et al.
Circulation. Heart Failure|January 12, 2018
Efficacy of Ranolazine in Patients With Symptomatic Hypertrophic Cardiomyopathy: The RESTYLE-HCM Randomized, Double-Blind, Placebo-Controlled StudyIacopo Olivotto, Paolo G Camici, Piera Angelica Merlini, et al.
Journal of the American College of Cardiology|March 21, 2015
Short- versus long-term dual antiplatelet therapy after drug-eluting stent implantation: an individual patient data pairwise and network meta-analysisTullio Palmerini, Diego Sangiorgi, Marco Valgimigli, et al.
The American Journal of Cardiology|July 20, 2014
Significance of sarcomere gene mutations analysis in the end-stage phase of hypertrophic cardiomyopathyElena Biagini, Iacopo Olivotto, Maria Iascone, et al.
European Journal of Heart Failure|August 15, 2023
Diagnosis and management of patients with left ventricular hypertrophy: Role of multimodality cardiac imaging. A scientific statement of the Heart Failure Association of the European Society of CardiologyBrenda Moura, Alberto Aimo, Abdallah Al-Mohammad, et al.
Circulation|September 16, 2009
Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main typesClaudio Rapezzi, Giampaolo Merlini, Candida C Quarta, et al.
Heart (British Cardiac Society)|October 28, 2018
Effectiveness of the 2014 European Society of Cardiology guideline on sudden cardiac death in hypertrophic cardiomyopathy: a systematic review and meta-analysisConstantinos O'Mahony, Mohammed Majid Akhtar, Zacharias Anastasiou, et al.
European Radiology|May 11, 2023
Chest CT opportunistic biomarkers for phenotyping high-risk COVID-19 patients: a retrospective multicentre studyAnna Palmisano, Chiara Gnasso, Alberto Cereda, et al.
European Journal of Heart Failure|May 5, 2022
Incidence and risk factors for pacemaker implantation in light-chain and transthyretin cardiac amyloidosisAldostefano Porcari, Maddalena Rossi, Francesco Cappelli, et al.
JACC. Cardiooncology|November 29, 2022
Prognosis of Transthyretin Cardiac Amyloidosis Without Heart Failure SymptomsEsther Gonzalez-Lopez, Luis Escobar-Lopez, Laura Obici, et al.
Pageof 41

Showing results (351-360 of 404) with videos related to

Sort By:
Pageof 41
Journal of Cardiovascular Medicine (Hagerstown, Md.)|October 15, 2008
Anticoagulant drugs in noncompaction: a mandatory therapy?Giovanni Fazio, Giovanni Corrado, Elisabetta Zachara, et al.
Circulation. Heart Failure|January 12, 2018
Efficacy of Ranolazine in Patients With Symptomatic Hypertrophic Cardiomyopathy: The RESTYLE-HCM Randomized, Double-Blind, Placebo-Controlled StudyIacopo Olivotto, Paolo G Camici, Piera Angelica Merlini, et al.
Journal of the American College of Cardiology|March 21, 2015
Short- versus long-term dual antiplatelet therapy after drug-eluting stent implantation: an individual patient data pairwise and network meta-analysisTullio Palmerini, Diego Sangiorgi, Marco Valgimigli, et al.
The American Journal of Cardiology|July 20, 2014
Significance of sarcomere gene mutations analysis in the end-stage phase of hypertrophic cardiomyopathyElena Biagini, Iacopo Olivotto, Maria Iascone, et al.
European Journal of Heart Failure|August 15, 2023
Diagnosis and management of patients with left ventricular hypertrophy: Role of multimodality cardiac imaging. A scientific statement of the Heart Failure Association of the European Society of CardiologyBrenda Moura, Alberto Aimo, Abdallah Al-Mohammad, et al.
Circulation|September 16, 2009
Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main typesClaudio Rapezzi, Giampaolo Merlini, Candida C Quarta, et al.
Heart (British Cardiac Society)|October 28, 2018
Effectiveness of the 2014 European Society of Cardiology guideline on sudden cardiac death in hypertrophic cardiomyopathy: a systematic review and meta-analysisConstantinos O'Mahony, Mohammed Majid Akhtar, Zacharias Anastasiou, et al.
European Radiology|May 11, 2023
Chest CT opportunistic biomarkers for phenotyping high-risk COVID-19 patients: a retrospective multicentre studyAnna Palmisano, Chiara Gnasso, Alberto Cereda, et al.
European Journal of Heart Failure|May 5, 2022
Incidence and risk factors for pacemaker implantation in light-chain and transthyretin cardiac amyloidosisAldostefano Porcari, Maddalena Rossi, Francesco Cappelli, et al.
JACC. Cardiooncology|November 29, 2022
Prognosis of Transthyretin Cardiac Amyloidosis Without Heart Failure SymptomsEsther Gonzalez-Lopez, Luis Escobar-Lopez, Laura Obici, et al.
Pageof 41